Literature DB >> 12234976

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

Christopher E Touloukian1, Wolfgang W Leitner, Paul F Robbins, Yong F Li, Xiaoqiang Kang, Rejean Lapointe, Patrick Hwu, Steven A Rosenberg, Nicholas P Restifo.   

Abstract

CD4(+) T cells can recognize "self" tumor antigens, but the impact of tumor cell expression of self-antigens on CD4(+) T-cell function in humans is unknown. Here, we identify a new epitope (ISPNSVFSQWRVVCDSLEDYD) derived from tyrosinase-related protein-1 (TRP-1) using a predictive algorithm and mice transgenic for a chimeric HLA-DRB1*0401 molecule. We then compared the functions of TRP-1-epitope-specific, CD4(+) T-cell responses in normal healthy individuals to those found in patients with metastatic malignant melanoma. Surprisingly, we found that tumor-bearing patients had significantly higher levels of TRP-1-specific, CD4(+) T-cell function than healthy volunteers as measured ex vivo. Thus, the net effect of "self" antigen expression by tumor cells was the enhancement of tumor antigen-specific CD4(+) T-cell function, rather than immunosuppression. These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234976      PMCID: PMC2248802     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

2.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

Authors:  K Staveley-O'Carroll; E Sotomayor; J Montgomery; I Borrello; L Hwang; S Fein; D Pardoll; H Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

3.  Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.

Authors:  F M Marincola; L Rivoltini; M L Salgaller; M Player; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-07

4.  CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.

Authors:  R Somasundaram; P Robbins; D Moonka; E Loh; F Marincola; A Patel; D Guerry; D Herlyn
Journal:  Int J Cancer       Date:  2000-01-15       Impact factor: 7.396

5.  Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.

Authors:  C E Touloukian; W W Leitner; S L Topalian; Y F Li; P F Robbins; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

6.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Authors:  W W Overwijk; D S Lee; D R Surman; K R Irvine; C E Touloukian; C C Chan; M W Carroll; B Moss; S A Rosenberg; N P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

Authors:  P P Lee; C Yee; P A Savage; L Fong; D Brockstedt; J S Weber; D Johnson; S Swetter; J Thompson; P D Greenberg; M Roederer; M M Davis
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

8.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.

Authors:  H Mizoguchi; J J O'Shea; D L Longo; C M Loeffler; D W McVicar; A C Ochoa
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

9.  Coupling and uncoupling of tumor immunity and autoimmunity.

Authors:  W B Bowne; R Srinivasan; J D Wolchok; W G Hawkins; N E Blachere; R Dyall; J J Lewis; A N Houghton
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

10.  CD4 T cells and their role in antitumor immune responses.

Authors:  R E Toes; F Ossendorp; R Offringa; C J Melief
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

View more
  17 in total

1.  Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Leroy N Hwang; Elke S Bergmann-Leitner; Steven E Finkelstein; Stephan Frank; Nicholas P Restifo
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

2.  Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Journal:  Vaccine       Date:  2006-05-06       Impact factor: 3.641

3.  High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.

Authors:  Andrew G Brandmaier; Wolfgang W Leitner; Sung P Ha; John Sidney; Nicholas P Restifo; Christopher E Touloukian
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

4.  Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer.

Authors:  Laura A Vella; Min Yu; Steven R Fuhrmann; Moustapha El-Amine; Diane E Epperson; Olivera J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

5.  Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.

Authors:  Sung P Ha; Nicholas D Klemen; Garrett H Kinnebrew; Andrew G Brandmaier; Jon Marsh; Giao Hangoc; Douglas C Palmer; Nicholas P Restifo; Kenneth Cornetta; Hal E Broxmeyer; Christopher E Touloukian
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

Review 6.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 7.  Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase.

Authors:  Karen Taraszka Hastings; Peter Cresswell
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

8.  Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.

Authors:  Wolfgang W Leitner; Leroy N Hwang; Michael J deVeer; Aimin Zhou; Robert H Silverman; Bryan R G Williams; Thomas W Dubensky; Han Ying; Nicholas P Restifo
Journal:  Nat Med       Date:  2002-12-23       Impact factor: 53.440

10.  Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.

Authors:  Maria R Parkhurst; John P Riley; Paul F Robbins; Steven A Rosenberg
Journal:  J Immunother       Date:  2004 Mar-Apr       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.